Patents Examined by Venkataraman Balasubramanian
  • Patent number: 10836728
    Abstract: The invention relates to certain substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: November 17, 2020
    Assignee: Mebias Discovery, Inc.
    Inventors: Brett A. Tounge, Shariff Bayoumy, Lawrence C. Kuo, Scott L. Dax
  • Patent number: 10836754
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: November 17, 2020
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Cyrille Lescop, Jasper Dingemanse, Andreas Krause
  • Patent number: 10829457
    Abstract: Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 10, 2020
    Assignee: CV6 THERAPEUTICS (NI) LIMITED
    Inventors: Mark Spyvee, Robert D. Ladner
  • Patent number: 10829482
    Abstract: The present invention is to provide a method of producing a glyceric acid ester which is easy for production and high in yield, and in which a pyridine to be used for the reaction is easily reused. Provided is a method of producing a compound represented by the following formula (II), including a step of oxidatively esterifying Compound A represented by the following formula (I) with Compound B selected from an organic nitroxyl radical, an N-hydroxy form thereof, and a salt containing an oxo ammonium cation of them, and an oxidizing agent in the presence of a pyridine having an alkyl substituent, wherein the use amount of Compound B is 0.0001 or more and 0.1 or less in terms of a molar ratio relative to Compound A: wherein, in the formulae (I) and (II), R1 and R2 each independently represent a hydrogen atom or a monovalent hydrocarbon group, or R1 and R2 are bonded to each other to form a divalent hydrocarbon group for constituting a ring structure.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: November 10, 2020
    Assignee: KAO CORPORATION
    Inventor: Takashi Aoki
  • Patent number: 10829459
    Abstract: A process is described, having a low-energy consumption and reduced ammonia consumption for the production of high-purity melamine, through the pyrolysis of urea, and the relative plant.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: November 10, 2020
    Assignee: EUROTECNICA MELAMINE, LUXEMBURG, ZWEIGNIEDERLASSUNG IN ITTIGEN
    Inventor: Roberto Santucci
  • Patent number: 10815216
    Abstract: The present invention relates to an improved process for the preparation of Aripiprazole Lauroxil of Formula (I).
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: October 27, 2020
    Assignee: NEULAND PHARMA RESEARCH PRIVATE LIMITED
    Inventors: Ponnaiah Ravi, Neela Praveen Kumar, Batthini Guruswamy, Krishnaiah Pendem, Satya Nagendra Kumar Lakkadasu, Mahesh Gattikoppula
  • Patent number: 10807985
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: October 20, 2020
    Assignee: Blueprint Medicines Corporation
    Inventor: Kevin J. Wilson
  • Patent number: 10800750
    Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: October 13, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
  • Patent number: 10800732
    Abstract: Disclosed are a series of malonamide derivatives having a chemical structure(I), their synthesis, and evaluation of their bioactivities against bacterial cell, bacterial-infected C. elegans and mice.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: October 13, 2020
    Assignees: NATIONAL TAIWAN UNIVERSITY, NATIONAL YANG-MING UNIVERSITY
    Inventors: Chung-Wai Shiau, Hao-Chieh Chiu
  • Patent number: 10800765
    Abstract: The present application discloses an indole as represented by formula (I) used as a CRTH2 inhibitor, and a pharmaceutically acceptable salt or tautomer of the indole, and an application of same in treating a disease related to a CRTH2 receptor.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: October 13, 2020
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yuanshan Yao, Bin Chen, Yuan Chen, Ao Li, Ran Xu, Zhensheng Huang, Dongdong Tian, Hongwei Li, Chengshuai Yang, Jian Li, Shuhui Chen
  • Patent number: 10799509
    Abstract: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: October 13, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
  • Patent number: 10793530
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: October 6, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner
  • Patent number: 10792285
    Abstract: The present invention relates to a pharmaceutical composition with enhanced stability, containing pemetrexed or a salt thereof, and a preparation method therefor. The present invention provides an injection preparation in liquid form containing pemetrexed, capable of ensuring sufficient stability during circulation and storage by selection of an optimum material and setting of an optimum concentration range in order to secure the stability of pemetrexed. The present invention can provide a pemetrexed preparation which is readily commercially prepared, can prevent microbial contamination occurring during lyophilization or reconstitution, and has enhanced convenience of administration and stability.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: October 6, 2020
    Assignee: Chong Kun Dang Pharmaceutical Corp.
    Inventors: Min Jae Joo, Hye Jin Seo, Shin Jung Park
  • Patent number: 10793577
    Abstract: Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: October 6, 2020
    Assignee: Akarna Therapeutics, Ltd.
    Inventors: Raju Mohan, Benjamin Anthony Pratt
  • Patent number: 10793545
    Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: October 6, 2020
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich Bothe, Holger Siebeneicher, Nicole Schmidt, Reinhard Nubbemeyer, Ulf Bömer, Judith Günther, Holger Steuber, Martin Lange, Christian Stegmann, Andreas Sutter, Alexandra Rausch, Christian Friedrich, Peter Hauff
  • Patent number: 10780092
    Abstract: The invention provides certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R1, R3, R4a, R5a, R5b, R6, and the subscript t are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases or disorders which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and disorders and for preparing pharmaceuticals for this purpose.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: September 22, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Alan Whitehead, Olga Ornoski, Subharekha Raghavan, Raphaelle Berger, Joie Garfunkle, Zhiqiang Yang, Gang Ji, Falong Jiang, Jianmin Fu
  • Patent number: 10774171
    Abstract: Energetic nitrogen-rich monomers represented by the general Formula I: wherein each of X1 and X2 is independently NR or a covalent bond, R is H or C1-4 alkyl, each of T1 and T2 is independently a moiety selected from the group consisting of a triazole moiety, a tetrazole moiety and a guanidine moiety, at least one of T1 and T2 being substituted by at least one polymerizable group, are disclosed herein, as well as polymers based thereon, and uses of such polymers.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: September 15, 2020
    Assignee: Technology Innovation Momentum Fund (Israel) Limited Partnership
    Inventors: Michael Gozin, Alex Aizikovich, Avital Shlomovich, Adva Cohen, Tali Pechersky
  • Patent number: 10774087
    Abstract: Provided is a novel compound or a salt thereof inhibiting MTHFD2 and useful for treating a disease caused by overexpression of MTHFD2, a disease involved in overexpression of MTHFD2 and/or a disease associated with overexpression of MTHFD2. Solution Provided is a sulfonamide derivative having a coumarin skeleton represented by the following formula (I) and having various substituents: wherein R1, R2, R3, R4, R5, R6 and R7 are the same as defined in the specification, and a salt thereof.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 15, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Masahiro Ota, Hidekazu Inoue, Junya Kawai, Hitoshi Ohki, Tadashi Toki
  • Patent number: 10765678
    Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: September 8, 2020
    Assignee: Array BioPharma Inc.
    Inventors: Donald T. Corson, Christopher M. Lindemann, Daniel J. Watson
  • Patent number: 10759812
    Abstract: The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: September 1, 2020
    Assignee: Sunshine Lake Pharma Co., Ltd.
    Inventors: Wanjun Tang, Xinye Yang, Zheng Gu, Chenlu Li, Zongyuan Zhang, Zhifu Wan, Xiaojun Wang, Yingjun Zhang